Search
Search Results
-
L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
Dopamine was initially considered as a mere intermediate in the noradrenaline synthesis but was then found to be a neurotransmitter. Its depletion...
-
Fear extinction rescuing effects of dopamine and L-DOPA in the ventromedial prefrontal cortex
The ventromedial prefrontal cortex (vmPFC; rodent infralimbic cortex (IL)), is posited to be an important locus of fear extinction-facilitating...
-
-
-
-
l-DOPA and consolidation of fear extinction learning among women with posttraumatic stress disorder
This study tested whether l -DOPA delivered during the consolidation window following fear extinction learning reduces subsequent fear responding...
-
Impact of the catechol-O-methyltransferase Val158Met polymorphism on the pharmacokinetics of l-dopa and its metabolite 3-O-methyldopa in combination with entacapone
In the pharmacotherapy of patients with Parkinson’s disease (PD), entacapone reduces the peripheral metabolism of l -dopa to 3- O -methyldopa (3-OMD),...
-
GMP production of 6-[18F]Fluoro-l-DOPA for PET/CT imaging by different synthetic routes: a three center experience
BackgroundThe radiofluorinated levodopa analogue 6-[ 18 F]F- l -DOPA (3,4-dihydroxy-6- 18 F- l -phenylalanine) is a commonly employed radiotracer for PET/CT...
-
Research advances on L-DOPA-induced dyskinesia: from animal models to human disease
L-3,4-dihydroxyphenylalanine (L-DOPA) was introduced about half a century ago and is still the most effective medicine for the treatment of...
-
Objective assessment of the effects of opicapone in Parkinson’s disease through kinematic analysis
BackgroundOpicapone (OPC) is a third-generation, selective peripheral COMT inhibitor that improves peripheral L-DOPA bioavailability and reduces OFF...
-
Advances in the automated synthesis of 6-[18F]Fluoro-L-DOPA
The neurotracer 6-[ 18 F]FDOPA has been, for many years, a powerful tool in PET imaging of neuropsychiatric diseases, movement disorders and brain...
-
Correction to: Advances in the automated synthesis of 6-[18F]Fluoro-L-DOPA
An amendment to this paper has been published and can be accessed via the original article.
-
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease: clinical and therapeutic considerations
Emerging studies suggest a correlation between elevated plasma homocysteine (hcy) levels and the risk of atherosclerosis, vascular disorders, and...
-
Head-to-head comparison between [68Ga]Ga-DOTA-NOC and [18F]DOPA PET/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas
PurposeTo compare the detection ability of 68 Ga-labelled DOTA-l-Nal3-octreotide ([ 68 Ga]Ga-DOTA-NOC) and 6-[ 18 F]fluoro-L-3,4-dihydroxyphenylalanine ([
-
Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates l-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset
In recent studies performed in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset model of Parkinson’s disease (PD), we have...
